Colitis ulcerosa: Kann eine Modulation der intestinalen Mikrobiota eine langfristige Remission bedingen?
| Autor: | Philip C. Grunert, Andreas Stallmach, Arndt Steube, Dietmar H. Pieper |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
biology
business.industry Gastrointestinal Microbiome Gastroenterology Gut flora biology.organism_classification medicine.disease Bioinformatics Ulcerative colitis law.invention Transplantation Clinical trial 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law medicine Genetic predisposition 030211 gastroenterology & hepatology 030212 general & internal medicine Colitis business |
| Zdroj: | Zeitschrift für Gastroenterologie. 57:834-842 |
| ISSN: | 1439-7803 0044-2771 |
| Popis: | Although the pathogenesis of ulcerative colitis (UC) remains elusive, substantial progress in understanding its development and progression has been achieved in the past decades, and novel effective treatment strategies have been developed. Changes in gut microbiota, environmental triggers, deregulation of immunological responses, and genetic predisposition have been identified as pathogenic key factors. There are several lines of clinical observations, which support a close connection of altered gut microbiota with the development and course of UC. Despite a plethora of microbiota alterations in UC, it is currently unclear whether the observed changes in inflammation are cause or effect of the altered microbiota state.Fecal microbiota transplantation (FMT) provides a novel, perhaps complementary, strategy to restore gut microbial diversity, bacterial richness, and microbial homeostasis in UC. FMT is an already established treatment option for recurrent Clostridioides difficile infection, and several case series and randomized controlled trials have described its use in UC. In this review, we evaluate recent efficacy and safety data on FMT for UC, discuss possible pitfalls and show possible areas of future development. Although FMT could become a promising treatment modality for UC, based on currently available data, FMT should be only performed in clinical trials as controlled studies focusing on long-term outcomes and safety are warranted. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|